Acknowledgements Medical writing and editorial support were provided by Nicole Cash, PhD, and Abbey Pearson, MSci, of Axis, a division of Spirit Medical Communications Group Limited (and were funded by Novo Nordisk Inc.) in accordance with Good Publication Practice 3 (GPP3) guidelines ( Ethics declarations Funding This trial and medical writing support for the publication were funded by Novo Nordisk A/S, Sborg, Denmark
Semaglutide/GLP-1 Semaglutide/GLP-1 is a glucagon-like peptide-1 receptor antagonist, more commonly known as GLP-1
An appropriate dose of your semaglutide injection is guaranteed if you inject in a fatty part of the body, prime your new pen, attach a new needle every use, and slowly count to 6 to avoid early pull out of the needle
Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinsons disease